WO2008066296A1 - Composition pharmaceutique contenant un composé à base de phénanthrènequinone pour système d'administration intestinale - Google Patents

Composition pharmaceutique contenant un composé à base de phénanthrènequinone pour système d'administration intestinale Download PDF

Info

Publication number
WO2008066296A1
WO2008066296A1 PCT/KR2007/006010 KR2007006010W WO2008066296A1 WO 2008066296 A1 WO2008066296 A1 WO 2008066296A1 KR 2007006010 W KR2007006010 W KR 2007006010W WO 2008066296 A1 WO2008066296 A1 WO 2008066296A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
active ingredient
formulation
intestine
substituted
Prior art date
Application number
PCT/KR2007/006010
Other languages
English (en)
Inventor
In Geun Jo
Sang-Ku Yoo
Myung-Gyu Park
Taehwan Kwak
Original Assignee
Mazence Inc.
Kt & G Co., Ltd..
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020070102478A external-priority patent/KR20080047969A/ko
Application filed by Mazence Inc., Kt & G Co., Ltd.. filed Critical Mazence Inc.
Priority to EP07834305A priority Critical patent/EP2094262A4/fr
Priority to JP2009538338A priority patent/JP2010510981A/ja
Priority to US12/515,013 priority patent/US20100234453A1/en
Publication of WO2008066296A1 publication Critical patent/WO2008066296A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to an intestine-targeted pharmaceutical composition comprising a Phenanthrenequinone-based compound. More specifically, the present invention relates to an oral pharmaceutical composition with formulation of an intestinal delivery system of a certain Phenanthrenequinone-based compound or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient.
  • naphthoquinone-based compound such as ⁇ -lapachone ⁇ 7,8-dihydro-2,2-dimethyl-2H-naphtho(2,3- b)dihydropyran-7,8-dione ⁇ , dunnione ⁇ 2,3,3-tirmethyl-2,3,4,5-tetrahydro-naphtho(2,3-b) dihydrofuran-6,7-dione ⁇ , ⁇ -dunnione ⁇ 2,3,3-tirmethyl-2,3,4,5-tetrahydro-naphtiio(2,3- b)dihydrofuran-6,7-dione ⁇ , nocardinone A, nocardinone B, lantalucratin A, lantalucratin B, lantalucratin C and the like is effective for
  • the aforesaid naphthoquinone-based compound is a sparingly-soluble material which is soluble at a low degree of about 2 to 10% only in high-solubility solvents, such as CH 2 Cl 2 , CHCl 3 , CH 2 ClCH 2 Cl, CH 3 CCI3, Monoglyme, and Diglyme, but is poorly soluble in other ordinary polar or nonpolar solvents.
  • high-solubility solvents such as CH 2 Cl 2 , CHCl 3 , CH 2 ClCH 2 Cl, CH 3 CCI3, Monoglyme, and Diglyme
  • the aforementioned highly-insoluble naphthoquinone-based compound has a disadvantage of a significant limit in formulation of the compound into desired pharmaceutical preparations. Even though physiological activity of the naphthoquinone-based compound is elucidated by the present applicant, a dosage form of the naphthoquinone-based compound is limited to a formulation for in vivo administration via intravenous injection.
  • the present applicant has proposed a novel phenanthrenequinone-based compound having the structure of the naphthoquinone-based compound (Korean Patent Application Nos. 2007-0040673).
  • the phenanthrenequinone-based compound has also sparingly- soluble problems.
  • the drugs can exert therapeutic effects only when an active ingredient is absorbed into the body in an amount exceeding a certain concentration; however, a variety of factors are implicated in bioavailability, the degree to which a drug or other substance becomes available to the target tissue after administration. Low bioavailability of the drug or substance raises serious problems in development of drug compositions.
  • the inventors of the present invention have discovered that when a sparingly-soluble phenanthrenequinone-based compound is formulated into an intestine-targeted pharmaceutical composition, it is possible to minimize inactivation of the active ingredient which may occur due to internal bodily environment such as stomach, it is possible to solve a problem of low bioavailability suffered by conventional oral administration, and finally it is possible to significantly improve pharmacokinetic properties of the phenanthrenequinone-based compound.
  • the present invention has been completed based on these findings.
  • an oral pharmaceutical composition wherein a phenanthrenequinone-based compound represented by Formula 1 below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient, is prepared into an intestine-targeted formulation:
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , % R 9 , Rio, Rn, Ru, Ri 3 , Ri 4 , Ri 5 and R 16 are each independently hydrogen, halogen, hydroxyl or Ci-C 6 alkyl, alkene or alkoxy, C 4 -Qo cycloalkyl, heterocycloalkyl, aryl or heteroaryl, or two substituents thereof may be taken together to form a cyclic structure or form a double bond;
  • X is selected from the group consisting of C(R)(R'), N(R"), O and S, wherein R, R' and
  • R" are each independently hydrogen or Ci-C 6 lower alkyl
  • n and n each independently are 0 or 1, with proviso that when m or n is 0, carbon atoms adjacent to m or n form a cyclic structure via a direct bond.
  • pharmaceutically acceptable salt means a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound.
  • Examples of the pharmaceutical salt may include acid addition salts of the compound (I) with acids capable of forming a non-toxic acid addition salt containing pharmaceutically acceptable anions, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid and hydroiodic acid; organic carbonic acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid and salicylic acid; or sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid.
  • inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid and hydroiodic acid
  • organic carbonic acids such as tartaric acid,
  • examples of pharmaceutically acceptable carboxylic acid salts include salts with alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium and magnesium, salts with amino acids such as arginine, lysine and guanidine, salts with organic bases such as dicyclohexylamine, N-methyl-D- glucamine, tris(hydroxymethyl)methylamine, diethanolamine, choline and triethylamine.
  • the compound in accordance with the present invention may be converted into salts thereof, by conventional methods well-known in the art
  • prodrug means an agent that is converted into the parent drug in vivo.
  • Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration, whereas the parent may be not.
  • the prodrugs may also have improved solubility in pharmaceutical compositions over the parent drug.
  • An example of a prodrug would be a compound of the present invention which is administered as an ester ("prodrug") to facilitate transport across a cell membrane where water-solubility is detrimental to mobility, but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water solubility is beneficial.
  • a further example of the prodrug might be a short peptide (polyamino acid) bonded to an acidic group, where the peptide is metabolized to reveal the active moiety.
  • the pharmaceutical compounds in accordance with the present invention can include a prodrug represented by Formula 1 a below as an active material:
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , Rs, R9, Rio, Rn, R12, R13, Rw, Ri 5 , R16 m, n and X are as defined in Formula 1.
  • R 17 and R 18 are each independently -SO 3 -Na + or substituent represented by Formula 2 below or a salt thereof,
  • R 19 and R 20 are each independently hydrogen or substituted or unsubstituted C 1 -C 20 linear alkyl or C 1 -C 20 branched alkyl
  • R 21 is selected from the group consisting of substituents i) to v ⁇ i) below:
  • Ci-C 20 linear alkyl or C 1 -C 20 branched alkyl substituted or unsubstituted Ci-C 20 linear alkyl or C 1 -C 20 branched alkyl
  • R, R' and R" are each independently hydrogen or substituted or unsubstituted Ci-C 20 linear alkyl or C 1 -C 20 branched alkyl, R 14 is selected from the group consisting of hydrogen, substituted or unsubstituted amine, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, 1 is selected from the 1-5;
  • k is selected from the 0-20, with proviso that when k is O, R 19 and R 20 are not anything, and R 21 is directly bond to a carbonyl group.
  • solvate means a compound of the present invention or a salt thereof, which further includes a stoichiometric or non-stoichiometric amount of a solvent bound thereto by non-covalent intermolecular forces.
  • Preferred solvents are volatile, non-toxic, and/or acceptable for administration to humans. Where the solvent is water, the solvate refers to a hydrate.
  • the term "isomer” means a compound of the present invention or a salt thereof, that has the same chemical formula or molecular formula but is optically or sterically different therefrom.
  • D type optical isomer and L type optical isomer can be present in the Formula 1 , depending on the Rr-R 16 types of substituents selected.
  • phenanthrenequinone-based compound is intended to encompass a compound per se, and a pharmaceutically acceptable salt, prodrug, solvate and isomer thereof.
  • alkyl refers to an aliphatic hydrocarbon group.
  • the alkyl moiety may be a "saturated alkyl” group, which means lhat it does not contain any alkene or alkyne moieties.
  • the alkyl moiety may also be an "unsaturated alkyl” moiety, which means that it contains at least one alkene or alkyne moiety.
  • alkene moiety refers to a group in which at least two carbon atoms form at least one carbon-carbon double bond
  • an “alkyne” moiety refers to a group in which at least two carbon atoms form at least one carbon-carbon triple bond.
  • heterocycloalkyl means a carbocyclic group in which one or more ring carbon atoms are substituted with oxygen, nitrogen or sulfur and which includes, for example, but is not limited to furan, Hiiophene, pyrrole, pyridine, pyrrolidine, oxazole, thiazole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isothiazole, triazole, thiadiazole, pyran, pyridine, piperidine, mo ⁇ holine, thiomo ⁇ holine, pyridazine, pyrimidine, pyrazine, piperazine and triazine.
  • aryl refers to an aromatic substituent group which has at least one ring having a conjugated pi ( ⁇ ) electron system and includes both carbocyclic aryl (for example, phenyl) and heterocyclic aryl (for example, pyridine) groups. This term includes monocyclic or fiised-ring polycyclic (Le., rings which share adjacent pairs of carbon atoms) groups.
  • heteroaryl refers to an aromatic group that contains at least one heterocyclic ring.
  • aryl or heteroaryl examples include, but are not limited to, phenyl, furan, pyran, pyridyl, pyrimidyl and triazyl.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 5 , R?, Rs, R9, Rio, Rn, R12, RB, Ri4, RIS and R 16 in Formula 1 in accordance with the present invention may be optionally substituted.
  • the substituent group(s) is(are) one or more group(s) individually and independently selected from cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylihio, cyano, halogen, carbonyl, thiocarbonyl, 0-carbamyl, N carbamyl, 0-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-siilfonamido, N-sulfonamido, C-carboxy, 0-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and amino including mono and di substituted amino, and protected derivatives thereof.
  • R 1 ⁇ R 20 and R 20 may be substituted by the
  • Compounds of Formula 3 below are compounds wherein m is 1, n is 0 and adjacent carbon atoms form a cyclic structure (furan ring) via a direct bond therebetween and are often referred to as 'furanotetrahy ⁇ rophenanthrene compounds' or 'furanotetrahydro-3,4- phenanthrenequinone' hereinafter.
  • composition means a mixture of a compound of Formula 1 as an active material and other components which are required for an intestine-targeted formulation.
  • tricyclic naphthoquinone pyrano-o-naphthoquinone and furano-o- naphthoquinone
  • tricyclic naphthoquinone pyrano-o-naphthoquinone and furano-o- naphthoquinone derivatives
  • One is to derive cyclization reaction using 3-allyl-2-hydroxy-l,4-naphthoquinone in acid catalyst condition, like in the following ⁇ -lapachone synthesis method.
  • Ru and R 12 are not hydrogen simultaneously, most of compounds of formula 1 were synthesized on the basis of that method.
  • 3-allyloxy-l,4-phenanthrenequinone can be obtained by deriving Diels-Alder reaction between 2-allyloxy-l,4-benzoquinone and styrene or 1-vinylcyclohexane derivatives and dehydrating the resulting intermediates using oxygen present in the air or oxidants such as NaIO 4 and DDQ.
  • 2-allyl-3-hydroxy-l,4-phenanthrenequinone of Lapachole form can be synthesized via Claisen rearrangement
  • 3-allyloxy-l,4-phenanthrenequinone is hydrolyzed to 3-oxy-l,4- phenanthrenequinone, in the condition of acid (H + ) or alkali (OH) catalyst, which is then reacted with various allyl halides to synthesize 2-allyl-3-hydroxy-l,4-phenanthrenequinone by C-alkylation.
  • the thus obtained 2-allyl-3-hydroxy-l,4-phenanthrenequinone derivatives are subject to cyclization in the condition of acid catalyst to synthesize various 3,4-phenanthrenequinone-based or 5,6,7,8- tetrahydro-3,4-naphthoquinone-based compounds.
  • an oral pharmaceutical composition passes through the stomach upon oral administration, is largely absorbed by the small intestine and then dif ⁇ used into all the tissues of the body, thereby exerting therapeutic effects on the target tissues.
  • the oral pharmaceutical composition according to the present invention enhances bioabso ⁇ tion and bioavailability of a certain phenanthrenequinone-based compound active ingredient via intestine-targeted formulation of the active ingredient. More specifically, when the active ingredient in the pharmaceutical composition according to the present invention is primarily absorbed in the stomach, and upper parts of the small intestine, the active ingredient absorbed into the body directly undergoes liver metabolism which is then accompanied by substantial degradation of the active ingredient, so it is impossible to exert a desired level of therapeutic effects. Qn the other hand, it is expected that when the active ingredient is largely absorbed around and downstream of the lower small intestine, the absorbed active ingredient migrates via lymph vessels to the target tissues to thereby exert high therapeutic effects.
  • the pharmaceutical composition according to the present invention targets up to the colon which is a final destination of the digestion process
  • it is possible to improve pharmacokinetic properties of the drug to significantly lower a critical effective dose of the active ingredient necessary for the treatment of the disease, and to obtain desired therapeutic effects even with administration of a trace amount of the active ingredient.
  • the oral pharmaceutical composition it is also possible to minimize the absorption variation of the drug by reducing the between- and within-individual variation of the bioavailability which may result from intragastric pH changes and dietary uptake patterns.
  • the intestine-targeted formulation according to the present invention is configured such that the active ingredient is largely absorbed in the small and large intestines, more preferably in the jejunum, and the ileum and colon corresponding to the lower small intestine, particularly preferably in the ileum or colon.
  • the intestine-targeted formulation may be designed by taking advantage of numerous physiological parameters of the digestive tract, through a variety of methods.
  • the intestine-targeted formulation may be prepared by (1) a formulation method based on a pH-sensitive polymer, (2) a formulation method based on a biodegradable polymer which is decomposable by an intestine-specific bacterial enzyme, (3) a formulation method based on a biodegradable matrix which is decomposable by an intestine- specific bacterial enzyme, or (4) a formulation method which allows release of a drug after a given lag time, and any combination thereof.
  • the intestine-targeted formulation (1) using the pH-sensitive polymer is a drug delivery system which is based on pH changes of the digestive tract.
  • the pH of the stomach is in a range of 1 to 3, whereas the pH of the small and large intestines has a value of 7 or higher, as compared to that of the stomach.
  • the pH-sensitive polymer may be used in order to ensure that the pharmaceutical composition reaches the lower intestinal parts without being affected by pH fluctuations of the digestive tract.
  • pH-sensitive polymer may include, but are not limited to, at least one selected from the group consisting of methacrylic acid- ethyl acrylate copolymer (Eudragit: Registered Trademark of Rohm Pharma GmbH), hydroxypropylmethyl cellulose phthalate (HPMCP) and a mixture thereof.
  • methacrylic acid- ethyl acrylate copolymer Eudragit: Registered Trademark of Rohm Pharma GmbH
  • HPP hydroxypropylmethyl cellulose phthalate
  • the pH-sensitive polymer may be added by a coating process.
  • addition of the polymer may be carried out by mixing the polymer in a solvent to form an aqueous coating suspension, spraying the resulting coating suspension to form a film coating, and drying the film coating.
  • the intestine-targeted formulation (2) using the biodegradable polymer which is decomposable by the intestine-specific bacterial enzyme is based on the utilization of a degradative ability of a specific enzyme that can be produced by enteric bacteria.
  • the specific enzyme may include azoreductase, bacterial hydrolase glycosidase, esterase, polysaccharidase, and the like.
  • the biodegradable polymer may be a polymer containing an azoaromatic linkage, for example, a copolymer of styrene and hydroxyethylmethacrylate (HEMA).
  • HEMA hydroxyethylmethacrylate
  • the active ingredient may be liberated into the intestine by reduction of an azo group of the polymer via the action of the azoreductase which is specifically secreted by enteric bacteria, for example, Bacteroides fragilis and Eubacteriwn limosum.
  • the biodegradable polymer may be a riaturally-occurring polysaccharide or a substituted derivative thereof.
  • the biodegradable polymer may be at least one selected from the group consisting of dextran ester, pectin, amylase, ethyl cellulose and a pharmaceutically acceptable salt thereof.
  • the active ingredient may be liberated into the intestine by hydrolysis of the polymer via the action of each enzyme which is specifically secreted by enteric bacteria, for example, Bifidobacteria and Bacterokks spp. These polymers are natural materials, and have an advantage of low risk of in vivo toxicity.
  • the intestine-targeted formulation (3) using the biodegradable matrix which is decomposable by an intestine-specific bacterial enzyme may be a form in which the biodegradable polymers are cross-linked to each other and are added to the active ingredient or the active ingredient-containing formulation.
  • the biodegradable polymer may include naturally- occurring polymers such as chondroitin sulfate, guar gum, chitosan, pectin, and the like.
  • the degree of drug release may vary depending upon the degree of cross-linking of the matrix-constituting polymer.
  • the biodegradable matrix may be a synthetic hydrogel based on N-substituted acrylamide.
  • a hydrogel synthesized by ⁇ oss-linking of N-tert-butylacryl amide with acrylic acid or ⁇ polymerization of 2- hydroxyethyl methacrylate and 4-methacryloyloxyazobenzene as the matrix.
  • the cross-linking may be, for example an azo linkage as mentioned above, and the formulation may be a form where the density of cross-linking is maintained to provide the optimal conditions for intestinal drug delivery and the linkage is degraded to interact with the intestinal mucous membrane when the drug is delivered to the intestine.
  • the intestine-targeted formulation (4) with time-course release of the drug after a lag time is a drug delivery system utilizing a mechanism that is allowed to release the active ingredient after a predetermined time irrespective of pH changes.
  • the formulation should be resistant to the gastric pH environment, and should be in a silent phase for 5 to 6 hours corresponding to a time period taken for delivery of the drug from the body to the intestine, prior to release of the active ingredient into the intestine.
  • the time-specific delayed-release formulation may be prepared by addition of the hydrogel prepared from copolymerization of polyethylene oxide with polyurethane.
  • the delayed-release formulation may have a configuration in which the formulation absorbs water and then swells while it stays within the stomach and the upper digestive tract of the small intestine, upon addition of a hydrogel having the above-mentioned composition after applying the drug to an insoluble polymer, and then migrates to the lower part of the small intestine which is the lower digestive tract and liberates the drug, and the lag time of drug is determined depending upon a length of the hydrogel.
  • ethyl cellulose may be used in the delayed- release dosage formulatioa EC is an insoluble polymer, and may serve as a factor to delay a drug release time, in response to swelling of a swelling medium due to water penetration or changes in the internal pressure of the intestines due to a peristaltic motion.
  • the lag time may be controlled by the thickness of EC.
  • hydroxypropylmethyl cellulose (HPMC) may also be used as a retarding agent that allows drug release after a given period of time by thickness control of the polymer, and may have a lag time of 5 to 10 hours.
  • the active ingredient may have a crystalline structure with a high degree of crystallinity, or a crystalline structure with a low degree of crystallinity.
  • the term "degree of crystallinity" is defined as the weight fraction of the crystalline portion of the total compound and may be determined by a conventional method known in the art. For example, measurement of the degree of crystallinity may be carried out by a density method or precipitation method which calculates the crystallinity degree by previous assumption of a preset value obtained by addition and/or reduction of appropriate values to/from each density of the crystalline portion and the amorphous portion, a method involving measurement of the heat of fusion, an X-ray method in which the crystallinity degree is calculated by separation of the crystalline diffraction fraction and the noncrystalline diffraction fraction from X-ray diffraction intensity distribution upon X-ray diffraction analysis, or an infrared method which calculates the crystallinity degree from a peak of the width between crystalline bands of the infrared absorption spectrum.
  • the crystallinity degree of the active ingredient is preferably 50% or less. More preferably, the active ingredient may have an amorphous structure from which the intrinsic crystallinity of the material was completely lost
  • the amorphous phenanthrenequinone-based compound exhibits a relatively high solubility, as compared to the crystalline phenanthrenequinone-based compound, and can significantly improve a dissolution rate and in vivo absorption rate of the drug.
  • the amorphous structure may be formed during preparation of the active ingredient into microparticles or fine particles (micronization of the active ingredient).
  • the microparticles may be prepared, for example by spray drying of active ingredients, melting methods involving formation of melts of active ingredients with polymers, co- precipitation involving formation of co-precipitates of active ingredients with polymers after dissolution of active ingredients in solvents, inclusion body formation, solvent volatilization, and the like. Preferred is spray drying. Even when the active ingredient is not of an amorphous structure, that is has a crystalline structure or semi-crystalline structure, micronization of the active ingredient into fine particles via mechanical milling contributes to improvement of solubility, due to a large specific surface area of the particles, consequently resulting in improved dissolution rate and bioabsorption rate of the active drug.
  • the spray drying is a method of making fine particles by dissolving the active ingredient in a certain solvent and the spray-drying the resulting solution. During the spray-drying process, a high percent of the crystaJlinity of the phenanthrenequinone-based compound is lost to thereby result in an amorphous state, and therefore the spray-dried product in the form of a fine powder is obtained.
  • the mechanical milling is a method of grinding the active ingredient into fine particles by applying strong physical force to active ingredient particles.
  • the mechanical milling may be carried out by using a variety of milling processes such as jet milling, ball milling, vibration milling, hammer milling, and the like. Particularly preferred is jet milling which can be carried out using an air pressure, at a temperature of less than 40 ° C .
  • the particle diameter of the active ingredient may be in a range of 5 nm to 500 ⁇ m. In this range, the particle agglomeration or aggregation can be maximally inhibited, and the dissolution rate and solubility can be maximized due to a high specific surface area of the particles.
  • a surfactant may be additionally added to prevent the particle agglomeration or aggregation which may occur during formation of the fine particles, and/or an antistatic agent may be additionally added to prevent the occurrence of static electricity.
  • a moisture-absorbent material may be further added during the milling process.
  • the phenanthrenequinone-based compound of Formula 1 has a tendency to be crystallized by water, so incorporation of the moisture-absorbent material inhibits recrystallization of the phenanthrenequinone-based compound over time and enables maintenance of increased solubility of compound particles due to micronization. Further, the moisture-absorbent material serves to suppress coagulation and aggregation of the pharmaceutical composition while not adversely affecting therapeutic effects of the active ingredient.
  • the surfactant may include, but are not limited to, anionc surfactants such as docusate sodium and sodium lauryl sulfate; cationic surfactants such as benzalkonium chloride, benzethonium chloride and cetrimide; nonionic surfactants such as glyceryl monooleate, polyoxyethylene sorbitan fatty acid ester, and sorbitan ester; amphophilic polymers such as polyethylene-polypropylene polymer and polyoxyethylene-polyoxypropylene polymer (Poloxamer), and GelucireTM series (Gattefosse Corporation, USA); propylene glycol monocaprylate, oleoyl macrogol-6-glyceride, linoleoyl macrogol-6-glyceride, caprylocaproyl macrogol-8-glyceride, propylene glycol monolaurate, and polyglyceryl-6-dioleate. These materials may be used alone or in any combination thereof.
  • moisture-absorbent material may include, but are not limited to, colloidal silica, light anhydrous silicic acid, heavy anhydrous silicic acid, sodium chloride, calcium silicate, potassium aluminosilicate, calcium aluminosilicate, and the like. These materials may be used alone or in any combination thereof.
  • moisture absorbents may also be used as the antistatic agent.
  • the surfactant, antistatic agent, and moisture absorbent are added in a certain amount that is capable of achieving the above-mentioned effects, and such an amount may be appropriately adjusted depending upon micronization conditions.
  • the additives may be used in a range of 0.05 to 20% by weight, based on the total weight of the active ingredient.
  • water-soluble polymers, solubiHzers and disintegration-promoting agents may be further added.
  • formulation of the composition into a desired dosage form may be made by mixing the additives and the particulate active ingredient in a solvent and spray-drying the mixture.
  • the water-soluble polymer is of help to prevent aggregation of the particulate active ingredients, by rendering surroundings of phenanthrenequinone-based compound molecules or particles hydrophilic to consequently enhance water solubility, and preferably to maintain the amorphous state of the active ingredient phenanthrenequinone-based compound.
  • the water-soluble polymer is a pH-independent polymer, and can bring about crystallinity loss and enhanced hydrophilicity of the active ingredient, even under the between- and within-individual variation of the gastrointestinal pH.
  • Preferred examples of the water-soluble polymers may include at least one selected from the group consisting of cellulose derivatives such as methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, ethyl cellulose, hydroxyethylmethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, sodium carboxymethyl cellulose, and carboxymethylethyl cellulose; polyvinyl alcohols; polyvinyl acetate, polyvinyl acetate phthalate, polyvinylpyrrolidone (PVP), and polymers containing the same; polyalkene oxide or polyalkene glycol, and polymers containing the same. Preferred is hydroxypropylmethyl cellulose.
  • an excessive content of the water-soluble polymer which is higher than a given level provides no further increased solubility, but disadvantageously brings about various problems such as overall increases in the hardness of the formulation, and non-penetration of an eluent into the formulation, by formation of films around the formulation due to excessive swelling of water-soluble polymers upon exposure to the eluent
  • the solubilizer is preferably added to maximize the solubility of the formulation by modifying physical properties of the phenanthrenequinone-based compound.
  • the solubilizer serves to enhance solubilization and wettability of the sparingly-soluble phenanthrenequinone-based compound, and can significantly reduce the bioavailability variation of the phenanthrenequinone-based compound originating from diets and the time difference of drug administration after dietary uptake.
  • the solubilizer may be selected from conventionally widely used surfactants or amphiphiles, and specific examples of the solubilizer may refer to the surfactants as defined above.
  • the disintegration-promoting agent serves to improve the drug release rate, and enables rapid release of the drug at the target site to thereby increase bioavailability of the drug.
  • Preferred examples of the disintegration-promoting agent may include, but are not limited to, at least one selected from the group consisting of Croscarmellose sodium, Crospovidone, calcium carboxymethylcellulose, starch glycolate sodium and lower substituted hydroxypropyl cellulose. Preferred is Croscarmellose sodium.
  • the solvent for spray drying is a material exhibiting a high solubility without modification of physical properties thereof and easy volatility during the spray drying process.
  • Preferred examples of such a solvent may include, but are not limited to, dichloromethane, chloroform, methanol, and ethanol. These materials may be used alone or in any combination thereof.
  • a content of solids in the spray solution is in a range of 5 to 50% by weight, based on the total weight of the spray solution.
  • the above-mentioned intestine-targeted formulation process may be preferably carried out for formulation particles prepared as above.
  • the oral pharmaceutical composition according to the present invention may be formulated by a process comprising the following steps:
  • the surfactant, moisture-absorbent material, water-soluble polymer, solubilizer and disintegration-promoting agent are as defined above.
  • the plasticizer is an additive added to prevent hardening of the coating, and may include, for example polymers such as polyethylene glycol.
  • formulation of the active ingredient may be carried out by sequential or concurrent spraying of vehicles of Step (b) and intestine-targeted coating materials of Step (c) onto jet-milled active ingredient particles of Step (a) as a seed.
  • the oral pharmaceutical composition suitable for use in the present invention contains the active ingredient in an amount effective to achieve its intended purpose, that is therapeutic purpose. More specifically, a therapeutically effective amount refers to an amount of the compound effective to prevent, alleviate or ameliorate symptoms of disease. Determination of the therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • the oral pharmaceutical composition according to the present invention is particularly effective for the treatment and/or prevention of metabolic diseases, degenerative diseases, and mitochondrial dysfunction-related diseases.
  • the metabolic diseases may include, but are not limited to, obesity, obesity complications, liver diseases, arteriosclerosis, cerebral apoplexy, myocardial infarction, cardiovascular diseases, ischemic diseases, diabetes, diabetes- related complications and inflammatory diseases.
  • Complications caused from obesity include, for example hypertension, myocardiac infarction, varicosis, pulmonary embolism, coronary artery diseases, cerebral hemorrhage, senile dementia, Parkinson's disease, type 2 diabetes, hyperlipidemia, cerebral apoplexy, various cancers (such as uterine cancer, breast cancer, prostate cancer, colon cancer and the like), heart diseases, gall bladder diseases, sleep apnea syndrome, arthritis, infertility, venous ulcer, sudden death, fatty liver, hypertrophic cardiomyopathy (HCM), thromboembolism, esophagitis, abdominal wall hernia (Ventral Hernia), urinary incontinence, cardiovascular diseases, endocrine diseases and the like.
  • Diabetic complications include, for example hyperlipidemia, hypertension, retinopathy, renal insufficiency, and the like.
  • Examples of the degenerative diseases may include Alzheimer's disease, Parkinson's disease and Huntington's disease.
  • Diseases arising from mitochondrial dysfunction may include for example, multiple sclerosis, encephalomyelitis, cerebral radiculitis, peripheral neuropathy, Reye's syndrome, Friedrich's ataxia, Alpers syndrome, MELAS, migraine, psychosis, depression, seizure and dementia, paralytic episode, optic atrophy, optic neuropathy, retinitis pigmentosa, cataract, hyperaldosteronemia, hypoparathyroidism, myopathy, amyotrophy, myoglobinuria, muscular hypotonia, myalgia, reduced exercise tolerance, renal tubulopathy, renal failure, hepatic failure, hepatic dysfunction, hepatomegaly, sideroblastic anemia (iron-deficiency anemia), neutropenia, thrombocytopenia, diarrhea, villous atrophy, multiple vomiting, dysphagia, constipation, sensorineural hearing loss (SNHL), mental retardation, epilepsy, and the like.
  • multiple sclerosis encephalomyelitis, cerebral radicu
  • treatment refers to stopping or delaying of the disease progress, when the drug is used in the subject exhibiting symptoms of disease onset.
  • prevention refers to stopping or delaying of symptoms of disease onset, when the drug is used in the subject exhibiting no symptoms of disease onset but having high risk of disease onset.
  • Example 1 Mcronization of active ingredient using Jet mill
  • Mcronizing of an active ingredient was carried out using a Jet mill (SJ-IOO, Nisshin, Japan). Operation was run at a supply pressure of 0.65 Mpa, and a feed rate of 16 to 20 g/hr.0.2 g of sodium lauryl sulfate (sodium lauryl sulfate) and 10 g of cryptotanshinone as a phenanthrenequinone-based compound were add to 100 ml of water and then ground for 10 hours. Micronized particles were recovered and a particle size was determined by zeta potential measurement. An average particle diameter was 1500 nm.
  • Cryptotanshinone per se or cryptotanshinone which was micronized in Example 1 was added to methanol. Then, a salt such as sodium chloride, a saccharide such as white sugar or lactose, or a vehicle such as microcrystalline cellulose, monobasic calcium phosphate, starch or mannitol, a lubricant such as magnesium stearate, talc or glyceryl behenate, and a solubilizer such as Poloxamer were added thereto, followed by homogeneous dispersion to prepare a spray-drying solution which will be used for subsequent spray-drying.
  • a salt such as sodium chloride
  • a saccharide such as white sugar or lactose
  • a vehicle such as microcrystalline cellulose, monobasic calcium phosphate, starch or mannitol
  • a lubricant such as magnesium stearate, talc or glyceryl behenate
  • solubilizer such as Poloxamer
  • Example 2 To the spray-dried product of Example 2 were added approximately an equal amount of a water-soluble polymer (hydroxypropylmethyl cellulose) relative to an active ingredient, and vehicles such as Croscarmellose sodium and light anhydrous silicic acid, and the mixture was formulated without causing interference of disintegration. A drug dissolution test was carried out in a buffer (pH 6.8). All the compositions exhibited drug dissolution of 90% or higher after 6 hours.
  • Experimental Example 2 Evaluation of relative bioavailability of spray-dried formulations in which the phenanthrenequinone-based compound is contained
  • the intestine-targeted formulation prepared in Example 3 was exposed to pH 1.2 and pH 6.8, respectively. After 6 hours, the intestine-targeted formulation was removed and washed, and a content of an active ingredient was analyzed by HPLC. An effective amount of the active ingredient was assessed as a measure of the acid resistance. The acid resistance exhibited a very excellent result of 90 to 100%, thus suggesting that the intestine-targeted formulation is chemically stable in the stomach or small intestine.
  • 10-week-old ob/ob male mice (Jackson Lab) as an obese mouse model of type 2 diabetes were purchased from Orient Co. (Kyungki-do, Korea) and were allowed to acclimate to a new environment of the breeding room for 10 days prior to experiments. Animals were fed a solid feed (P5053, Labdiet) as a laboratory animal feed. The ob/ob male mice were housed and allowed to acclimate to a new environment for 10 days, in a breeding room maintained at a temperature of 22 ⁇ 2 ° C, humidity of 55 ⁇ 5%, and a 12-h light/dark (UD) cycle (light from 8:00 am. to 8:00 p.m.).
  • UD light/dark
  • the thus-acclimated animals were randomly divided into four groups, each consisting of 7 animals: a control group with administration of sodium lauryl sulfate (10 mg/kg), a group with administration of simply finely-divided powder of a cryptotanshinone (400 mg/kg), a group with administration of a jet-milled cryptotanshinone, and a group with administration of an intestine-targeted formulation of a ground cryptotanshinone.
  • Each group of animals was given perorally (PO) 400 mg/kg of samples. Animals were fed solid feed pellets and water ad libitum. The changes in the body weight of animals in each group were measured.
  • an oral pharmaceutical composition according to the present invention increases a bioabso ⁇ tion rate and an in vivo retention time of an active ingredient to thereby improve pharmacokinetic properties of the drug.

Abstract

La présente invention concerne une composition pharmaceutique offrant une plus grande biodisponibilité et de meilleures propriétés pharmacocinétiques d'un médicament en augmentant la vitesse de bioabsorption et le temps de retenue in vivo d'un ingrédient actif par le biais d'une formulation ciblant l'intestin d'un composé à base de phénanthrènequinone particulier, ou d'un sel, promédicament, solvate ou isomère pharmaceutiquement acceptable de celui-ci comme ingrédient actif.
PCT/KR2007/006010 2006-11-07 2007-11-26 Composition pharmaceutique contenant un composé à base de phénanthrènequinone pour système d'administration intestinale WO2008066296A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07834305A EP2094262A4 (fr) 2006-11-27 2007-11-26 Composition pharmaceutique contenant un composé à base de phénanthrènequinone pour système d'administration intestinale
JP2009538338A JP2010510981A (ja) 2006-11-27 2007-11-26 腸送達系のためのフェナントレンキノンベース化合物を含有する医薬組成物
US12/515,013 US20100234453A1 (en) 2006-11-07 2007-11-26 Pharmaceutical composition containing phenanthrenequinone-based compound for intestine delivery system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20060117685 2006-11-27
KR10-2006-0117685 2006-11-27
KR1020070102478A KR20080047969A (ko) 2006-11-27 2007-10-11 페난스렌퀴논계 화합물 함유 장 표적용 약제 조성물
KR10-2007-0102478 2007-10-11

Publications (1)

Publication Number Publication Date
WO2008066296A1 true WO2008066296A1 (fr) 2008-06-05

Family

ID=39468044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/006010 WO2008066296A1 (fr) 2006-11-07 2007-11-26 Composition pharmaceutique contenant un composé à base de phénanthrènequinone pour système d'administration intestinale

Country Status (1)

Country Link
WO (1) WO2008066296A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2217225A2 (fr) * 2007-10-11 2010-08-18 Mazence Inc. Composition pharmaceutique contenant des particules micronisées d'un composé à base de naphtoquinone
EP2222295A2 (fr) * 2007-12-28 2010-09-01 Mazence Inc. Composition pharmaceutique utilisée dans le traitement et la prévention de maladies rénales

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541046B2 (en) * 2001-02-12 2003-04-01 Kaiyuan Wei Herbal composition and method for controlling body weight and composition
WO2005063232A1 (fr) * 2003-12-30 2005-07-14 Md Bioalpha Co., Ltd. Traitement de l'obesite et du syndrome metabolique avec des derives de tanshinone augmentant l'activite metabolique
WO2006088315A1 (fr) * 2005-02-16 2006-08-24 Md Bioalpha Co., Ltd. Composition pharmaceutique pour le traitement ou la prevention de pathologies comprenant l'obesite, le diabete, les syndromes metaboliques, les maladies neurodegeneratives, et les maladies liees a une dysfonction mitochondriale

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541046B2 (en) * 2001-02-12 2003-04-01 Kaiyuan Wei Herbal composition and method for controlling body weight and composition
WO2005063232A1 (fr) * 2003-12-30 2005-07-14 Md Bioalpha Co., Ltd. Traitement de l'obesite et du syndrome metabolique avec des derives de tanshinone augmentant l'activite metabolique
WO2006088315A1 (fr) * 2005-02-16 2006-08-24 Md Bioalpha Co., Ltd. Composition pharmaceutique pour le traitement ou la prevention de pathologies comprenant l'obesite, le diabete, les syndromes metaboliques, les maladies neurodegeneratives, et les maladies liees a une dysfonction mitochondriale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2094262A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2217225A2 (fr) * 2007-10-11 2010-08-18 Mazence Inc. Composition pharmaceutique contenant des particules micronisées d'un composé à base de naphtoquinone
EP2217225A4 (fr) * 2007-10-11 2012-12-19 Mazence Inc Composition pharmaceutique contenant des particules micronisées d'un composé à base de naphtoquinone
EP2222295A2 (fr) * 2007-12-28 2010-09-01 Mazence Inc. Composition pharmaceutique utilisée dans le traitement et la prévention de maladies rénales
EP2222295A4 (fr) * 2007-12-28 2011-04-13 Mazence Inc Composition pharmaceutique utilisée dans le traitement et la prévention de maladies rénales

Similar Documents

Publication Publication Date Title
US20100234453A1 (en) Pharmaceutical composition containing phenanthrenequinone-based compound for intestine delivery system
US10548880B2 (en) Solid dispersions comprising tacrolimus
ES2376238T3 (es) Composiciones de liberación modificada comprendiendo tacrolimus.
WO2008136642A1 (fr) Composition pharmaceutique à base de naphthoquinone pour le traitement ou la prévention de maladies mettant en jeu l'obésité, le diabète, le syndrome métabolique, les maladies neuro-dégénératives et les maladies de dysfonctionnement mitochondrial
WO2008066301A1 (fr) Composition anticancéreuse contenant un composé à base de naphtoquinone pour système d'administration intestinal
EP2217225A2 (fr) Composition pharmaceutique contenant des particules micronisées d'un composé à base de naphtoquinone
WO2015152433A1 (fr) Dispersion solide amorphe comprenant du paclitaxel, comprimé la comprenant, et son procédé de préparation
US20140154319A1 (en) Pharmaceutical composition for the treatment and prevention of cardiac disease
KR20100017109A (ko) 지프라시돈 제제
WO2008066295A1 (fr) Composition pharmaceutique contenant un composé à base de naphthoquinone pour système d'administration intestinale
US20090124680A1 (en) Use of prodrug composition containing naphthoquinone-based compound for manufacture of medicament for treatment or prevention of diseases involving metabolic syndrome
US20110311625A1 (en) Solid dosage forms of fenofibrate
WO2021220295A1 (fr) Compositions pharmaceutiques à libération immédiate comprenant du palbociclib
WO2008066296A1 (fr) Composition pharmaceutique contenant un composé à base de phénanthrènequinone pour système d'administration intestinale
US20130302422A1 (en) Pharmaceutical composition for treatment and prevention of kidney diseases
WO2008066298A1 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
WO2008066300A1 (fr) Composition pharmaceutique à base de naphtoquinone pour le traitement ou la prévention de maladies impliquant l'obésité, le diabète, le syndrome d'insulino-résistance, les maladies neurodégénératives, et les maladies à dysfonctions mitochondriales
CN114727995A (zh) 优替德隆的固体口服制剂

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780043856.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07834305

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009538338

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097010384

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007834305

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE